Cargando…
Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention
Due to the aging of the populations of developed countries and a common occurrence of risk factors, it is increasingly probable that a patient may have both cancer and cardiovascular disease. In addition, cytotoxic agents and targeted therapies used to treat cancer, including classic chemotherapeuti...
Autores principales: | Albini, Adriana, Pennesi, Giuseppina, Donatelli, Francesco, Cammarota, Rosaria, De Flora, Silvio, Noonan, Douglas M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2802286/ https://www.ncbi.nlm.nih.gov/pubmed/20007921 http://dx.doi.org/10.1093/jnci/djp440 |
Ejemplares similares
-
Permissive Cardiotoxicity: The Clinical Crucible of Cardio-Oncology
por: Porter, Charles, et al.
Publicado: (2022) -
Gender Differences in Diagnosis, Prevention, and Treatment of Cardiotoxicity in Cardio-Oncology
por: Simek, Shawn, et al.
Publicado: (2022) -
Leveraging the Cardio-Protective and Anticancer Properties of Resveratrol in Cardio-Oncology
por: Abdelgawad, Ibrahim Y., et al.
Publicado: (2019) -
Cardio-Oncology: Mechanisms, Drug Combinations, and Reverse Cardio-Oncology
por: Liang, Zehua, et al.
Publicado: (2022) -
Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy
por: Han, Xinqiang, et al.
Publicado: (2017)